Remibrutinib

Overview

Remibrutinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4483575).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Remibrutinib expires 19 Jan 2043 and exclusivity 30 Sept 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide

Canonical SMILES

CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C

InChIKey

CUABMPOJOBCXJI-UHFFFAOYSA-N